Second vaccine trial for coronavirus begins in U.S.

A researcher works on the development of a vaccine against the new coronavirus COVID-19, in Belo Horizonte, state of Minas Gerais, Brazil, on March 26, 2020. (Photo by DOUGLAS MAGNO/AFP via Getty Images)

Researchers in the United States have opened another safety test of an experimental vaccine for COVID-19.

The drug, developed by Inovio Pharmaceuticals is part of a worldwide effort to curb the spread of the virus.

Inovio will test two doses of the vaccine on 40 healthy volunteers at its Kansas City research lab.

Inovio’s researchers package a section of the virus’s genetic code inside a piece of synthetic DNA that’s injected in a skin-deep shot, and those cells act as a mini-factory to produce harmless protein copies while the body’s immune system produces antibodies against them that would also block the virus.

The early-stage studies will determine whether the vaccine is safe enough for larger tests.

Even if research goes well, it’s expected to be a year or more until the drug is widely available.

Another vaccine candidate backed by the National Institutes of Health Works similarly, except it uses a type of genetic code called Messenger RNA.

Neither vaccine is made using the actual virus, meaning there’s no chance of getting infected from the shot. 


Get breaking news alerts in the FOX5NY News app. It is FREE!

Download for iOS or Android